Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late

Adriano M. Pellicelli, Marzia Montalbano, Raffaella Lionetti, Christine Durand, Peter Ferenci, Gianpiero D'Offizi, Viola Knop, Andrea Telese, Ilaria Lenci, Arnaldo Andreoli, Stefan Zeuzem, Mario Angelico

Research output: Contribution to journalArticle

Abstract

Background: We evaluated efficacy and safety of sofosbuvir and daclatasvir. ±. ribavirin in liver transplant recipients with severe recurrent hepatitis C. Methods: Patients included in an international compassionate use programme for treatment with sofosbuvir and daclatasvir. ±. ribavirin for 24 weeks were prospectively studied. Serum hepatitis C virus RNA was measured at treatment weeks 4, 12, and 24 and during follow-up at weeks 4, 8, and 12. Results: Twelve patients (3 with fibrosing cholestatic hepatitis and 9 with cirrhosis; median model for end-stage liver disease score 20) received sofosbuvir 400. mg/day. +. daclatasvir 60. mg/day, and 6 patients (50%) also received ribavirin 200-800. mg/day. Nine patients completed 24 weeks of treatment (75%), and all had undetectable hepatitis C virus RNA at week 24; 3 patients died (25%, liver failure, gastrointestinal bleeding and sepsis); 4 patients experienced severe liver disease-related adverse events. Post-treatment hepatitis C virus RNA was available for 5 patients (week 8, n=. 2; week 4, n=. 3) and was undetectable in all cases. Mean Child-Pugh score and albumin level improved significantly at week 24. No changes in immunosuppressant doses were needed. Conclusion: All-oral sofosbuvir plus daclatasvir combination shows high virological efficacy in liver transplant recipients and does not interact with immunosuppressants. All adverse events were unrelated to study drugs. These data strongly suggest that this combination must be initiated before decompensation.

Original languageEnglish (US)
Pages (from-to)923-927
Number of pages5
JournalDigestive and Liver Disease
Volume46
Issue number10
DOIs
StatePublished - Jan 1 2014

Keywords

  • Cholestatic hepatitis
  • Cirrhosis
  • Daclatasvir
  • Direct antiviral agents
  • Disease recurrence
  • HCV
  • MELD
  • Sofosbuvir

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late'. Together they form a unique fingerprint.

  • Cite this

    Pellicelli, A. M., Montalbano, M., Lionetti, R., Durand, C., Ferenci, P., D'Offizi, G., Knop, V., Telese, A., Lenci, I., Andreoli, A., Zeuzem, S., & Angelico, M. (2014). Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late. Digestive and Liver Disease, 46(10), 923-927. https://doi.org/10.1016/j.dld.2014.06.004